Sotrovimab
Sotrovimab is a monoclonal antibody used for the treatment of COVID-19. It is designed to target the spike protein of the SARS-CoV-2 virus, which is responsible for the virus's entry into human cells. Sotrovimab is developed by GlaxoSmithKline and Vir Biotechnology.
Mechanism of Action[edit]
Sotrovimab works by binding to the spike protein of the SARS-CoV-2 virus, thereby preventing the virus from attaching to and entering human cells. This action helps to neutralize the virus and reduce the severity of the disease.
Clinical Use[edit]
Sotrovimab is authorized for emergency use in several countries for the treatment of mild to moderate COVID-19 in patients who are at high risk of progressing to severe disease, including hospitalization or death. It is administered via intravenous infusion.
Efficacy[edit]
Clinical trials have shown that sotrovimab significantly reduces the risk of hospitalization and death in high-risk patients with COVID-19. The antibody has been found to retain activity against multiple variants of the virus, including the Delta variant and Omicron variant.
Side Effects[edit]
Common side effects of sotrovimab include infusion-related reactions, such as fever, chills, and headache. Serious adverse events are rare but can include hypersensitivity reactions.
Regulatory Status[edit]
Sotrovimab has received Emergency Use Authorization (EUA) from the United States Food and Drug Administration (FDA) and similar authorizations from other regulatory bodies around the world.
See Also[edit]
- Monoclonal antibody
- COVID-19
- SARS-CoV-2
- GlaxoSmithKline
- Vir Biotechnology
- Emergency Use Authorization
References[edit]
